Loading regimen required to rapidly achieve therapeutic trough plasma concentration of teicoplanin and evaluation of clinical features

Clinical Pharmacology: Advances and Applications

Volumn 4, Issue 1, 2012, Pages 71-75

  Seki, Masafumi ^a   Yabuno, Kaori ^a   Miyawaki, Koji ^a   Miwa, Yoshihiro ^a   Tomono, Kazunori ^a  

^a OSAKA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Adverse effect; Dosing regimen; MRSA; Pharmacokinetics and pharmacodynamics; Staphylococcus aureus; Therapeutic drug monitoring

Indexed keywords

TEICOPLANIN; VANCOMYCIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; EVENING DOSAGE; HUMAN; LIVER TOXICITY; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; NEPHROTOXICITY; RETROSPECTIVE STUDY;

EID: 84870410037     PISSN: None     EISSN: 11791438     Source Type: Journal    
DOI: 10.2147/CPAA.S37528     Document Type: Article

References (20)

1. Gemmell CG, Edwards DI, Fraise AP, Gould FK, Ridgway GL, Warren RE; Joint Working Party of the British Society for Joint Working Party of the British Society for Antimicrobial Chemotherapy, Hospital Infection Society and Infection Control Nurses Association. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother. 2006;57: 589-608.
2. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52:285-292.
3. MacGowan AP. Pharmacodynamics, pharmacokinetics, and therapeutic drug monitoring of glycopeptides. Ther Drug Monit. 1998;20: 473-477.
4. MacGowan AP, Bowker KE. Pharmacodynamics of antimicrobial agents and rationale for their dosing. J Chemother. 1997;9:64-73.
5. Weinbren M, Struthers K. Emergence of Staphylococcus aureus (MRSA) with reduced susceptibility to teicoplanin during therapy. J Antimicrob Chemother. 2002;50:306-307.
6. Ueda T, Takesue Y, Nakajima K, et al. Evaluation of teicoplanin dosing designs to achieve a new target trough concentration. J Infect Chemother. 2012;18:296-302.
7. Matsumoto K, Kanazawa N, Ikawa K, et al. Determination of teicoplanin trough concentration target and appropriate total dose during the first 3 days: a retrospective study in patients with MRSA infections. J Infect Chemother. 2010;16:193-199.
8. Brink AJ, Richards GA, Cummins RR, et al. Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis. Int J Antimicrob Agents. 2008; 32:455-458.
9. Pea F, Viale P, Candoni A, et al. Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages. Clin Pharmacokinet. 2004;43:405-415.
10. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66:82-98.
11. Senior JR. Monitoring for hepatotoxicity: what is the predictive value of liver "function" tests? Clin Pharmacol Ther. 2009;85:331-334.
12. Wang JT, Liao HI, Wu Lin FL, Chang SC. Loading dose required to achieve rapid therapeutic teicoplanin trough plasma concentration in patients with multidrug-resistant gram-positive infections. Basic Clin Pharmacol Toxicol. 2012;110:416-420.
13. Lamont E, Seaton RA, Macpherson M, Semple L, Bell E, Thomson AH. Development of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programme. J Antimicrob Chemother. 2009;64:181-187.
14. Mimoz O, Rolland D, Adoun M, et al. Steady-state trough serum and epithelial lining fluid concentrations of teicoplanin 12 mg/kg per day in patients with ventilator-associated pneumonia. Intensive Care Med. 2006;32:775-779.
15. Pea F, Brollo L, Viale P, Pavan F, Furlanut M. Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose. J Antimicrob Chemother. 2003;51: 971-975.
16. Svetitsky S, Leibovici L, Paul M. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob Agents Chemother. 2009;53:4069-4079.
17. Van der Auwera P, Meunier F, Ibrahim S, Kaufman L, Derde MP, Tulkens PM. Pharmacodynamic parameters and toxicity of netilmicin (6 milligrams/kilogram/day) given once daily or in three divided doses to cancer patients with urinary tract infection. Antimicrob Agents Chemother. 1991;35:640-647.
18. Yoshida M, Matzno S, Namba H, Nishikata M, Matsuyama K. Statistical analysis of the adverse effects of glycopeptide antibiotics, based on pharmacokinetics and toxicokinetics (PK/TK). J Infect Chemother. 2006;12:114-118.
19. Frye RF, Job ML, Dretler RH, Rosenbaum BJ. Teicoplanin nephrotoxicity: first case report. Pharmacotherapy. 1992;12:240-242.
20. Wilson APR, Grunegerg R. Safety. In: Teicoplanin; The First Decade. Abingdon, UK: The Medicine Group (Education) Ltd; 1997:137-144.